
Gilead Sciences (GILD) has accused the U.S. government of breaching several contracts and “secretly” obtaining patents stemming from research that led to the ground-breaking Truvada HIV-prevention pill.
In a lawsuit filed late Friday, the drug maker claimed the Centers for Disease Control and Prevention violated the terms of a 15-year-old collaboration by failing to notify the company of patents that were later sought and awarded on the research.
What is it?
STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.
What's included?
- Daily reporting and analysis
- The most comprehensive industry coverage from a powerhouse team of reporters
- Subscriber-only newsletters
- Daily newsletters to brief you on the most important industry news of the day
- STAT+ Conversations
- Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
- Exclusive industry events
- Premium access to subscriber-only networking events around the country
- The best reporters in the industry
- The most trusted and well-connected newsroom in the health care industry
- And much more
- Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.